Business Context and Reporting Period
This Form 8-K Current Report was filed by CTS Corporation on April 4, 2018. The report details corporate governance changes effective April 2, 2018, specifically regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members.
- New Director Appointment: Alfonso G. Zulueta was elected to fill the resulting vacancy.
- Director Background: Mr. Zulueta is the President of Lilly International and Senior Vice President of Eli Lilly and Company, with over 30 years of experience in global pharmaceutical operations.
Guidance, Outlook, and Compensation
Compensation: As a non-employee director, Mr. Zulueta will receive compensation consistent with the Company's other non-employee directors, as previously disclosed in the definitive proxy statement on Schedule 14A filed on April 5, 2017.
Indemnification: The Company will enter into an Indemnification Agreement with Mr. Zulueta, utilizing the form previously disclosed in Exhibit 10.1 of the Form 8-K filed on February 18, 2015.
Outlook and Risks: The filing text does not provide a clear value for future guidance, management commentary on business outlook, or specific risk factors beyond standard governance disclosures.
Key Facts for Investor Verification
- Verify the effective date of the board expansion (April 2, 2018).
- Confirm Mr. Zulueta's current role at Eli Lilly and Company to assess potential conflicts of interest or strategic alignment.
- Review the Schedule 14A filed on April 5, 2017, for specific non-employee director compensation details.
- Check the Form 8-K filed on February 18, 2015, for the standard Indemnification Agreement terms.